<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700241</url>
  </required_header>
  <id_info>
    <org_study_id>METC 20-0.78</org_study_id>
    <nct_id>NCT04700241</nct_id>
  </id_info>
  <brief_title>Nitrate and Brain Insulin-Sensitivity</brief_title>
  <acronym>NO-BRAINS</acronym>
  <official_title>Acute Effects of Inorganic Nitrate on Brain Insulin-sensitivity in Abdominally Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disturbances in brain insulin-sensitivity are not only observed in abdominal obesity and type&#xD;
      2 diabetes mellitus (T2D), but also during brain aging and in dementia. Inorganic nitrate may&#xD;
      improve brain insulin-sensitivity, which can be quantified by measuring the gray-matter&#xD;
      cerebral blood flow (CBF) response to intranasally administered insulin, through beneficial&#xD;
      effects on brain vascular function. Therefore, we now hypothesize that inorganic nitrate,&#xD;
      which can be found in several vegetables such as beetroot, improves brain&#xD;
      insulin-sensitivity, as assessed by the gray-matter CBF response to intranasally administered&#xD;
      insulin, in abdominally obese men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Actual">May 5, 2021</completion_date>
  <primary_completion_date type="Actual">May 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain insulin sensitivity</measure>
    <time_frame>Change from placebo intervention at 2 hours after supplement intake</time_frame>
    <description>MRI arterial spin labeling, cerebral blood flow measurements before and after a nasal insulin spray</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain vascular function</measure>
    <time_frame>Change from placebo intervention at 2 hours after supplement intake</time_frame>
    <description>MRI arterial spin labeling, cerebral blood flow measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function markers</measure>
    <time_frame>Change from fasting at 4 hours after supplement intake</time_frame>
    <description>Flow-mediated vasodilation (FMD) of the brachial and femoral artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressure test</measure>
    <time_frame>Change from placebo at 4 hours after supplement intake</time_frame>
    <description>Carotid artery response to cold pressure test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers (1)</measure>
    <time_frame>Change from placebo at 4 hours after supplement intake</time_frame>
    <description>Plasma markers for low-grade systemic inflammation (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers (2)</measure>
    <time_frame>Change from placebo at 4 hours after supplement intake</time_frame>
    <description>Plasma marker for endothelial dysfunction (NOx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers (3)</measure>
    <time_frame>Change from placebo at 4 hours after supplement intake</time_frame>
    <description>Office blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers (4)</measure>
    <time_frame>During the 5.5 hours following supplement intake</time_frame>
    <description>Plasma brain derived neurotrophic factor (BDNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial metabolism (1)</measure>
    <time_frame>During the 5.5 hours following supplement intake</time_frame>
    <description>Serum lipid metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial metabolism (2)</measure>
    <time_frame>During the 5.5 hours following supplement intake</time_frame>
    <description>Plasma glucose metabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Nitrate</condition>
  <condition>Brain Insulin-sensitivity</condition>
  <condition>Vascular Function</condition>
  <arm_group>
    <arm_group_label>Potassium nitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this experimental day, men will receive 10 mmol of potassium nitrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During this experimental day, men will receive an isomolar dose of potassium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium nitrate</intervention_name>
    <description>Acute intervention (5.5 hours)</description>
    <arm_group_label>Potassium nitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute intervention (5.5 hours)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men;&#xD;
&#xD;
          -  Aged between 18 - 60 years;&#xD;
&#xD;
          -  Waist circumference &gt; 102 cm (abdominally obese);&#xD;
&#xD;
          -  Fasting plasma glucose ≤ 7.0 mmol/L;&#xD;
&#xD;
          -  Fasting serum total cholesterol ≤ 8.0 mmol/L;&#xD;
&#xD;
          -  Systolic blood pressure &lt; 160 mmHg and diastolic blood pressure &lt; 100 mmHg;&#xD;
&#xD;
          -  Stable body weight (weight gain or loss &lt; 3 kg in the past three months);&#xD;
&#xD;
          -  Willingness to give up being a blood donor from 8 weeks before the start of the study,&#xD;
             during the study and for 4 weeks after completion of the study;&#xD;
&#xD;
          -  Willingness not to use antibacterial mouth wash or toothpaste, chewing-gum and&#xD;
             tongue-scraping a week before the study;&#xD;
&#xD;
          -  No difficult venipuncture as evidenced during the screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women;&#xD;
&#xD;
          -  Left-handedness;&#xD;
&#xD;
          -  Current smoker, or smoking cessation &lt; 12 months;&#xD;
&#xD;
          -  Diabetic patients;&#xD;
&#xD;
          -  Familial hypercholesterolemia;&#xD;
&#xD;
          -  Abuse of drugs;&#xD;
&#xD;
          -  More than 3 alcoholic consumptions per day;&#xD;
&#xD;
          -  Use of products or dietary supplements known to interfere with the main outcomes as&#xD;
             judged by the principal investigators;&#xD;
&#xD;
          -  Use medication to treat blood pressure, lipid or glucose metabolism;&#xD;
&#xD;
          -  Pharmacological treatment advised based on the Dutch general practitioners'&#xD;
             association (NHG) for cardiovascular risk management;&#xD;
&#xD;
          -  Use of an investigational product within another biomedical intervention trial within&#xD;
             the previous 1-month;&#xD;
&#xD;
          -  Severe medical conditions that might interfere with the study, such as epilepsy,&#xD;
             asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease,&#xD;
             inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis;&#xD;
&#xD;
          -  Active cardiovascular disease like congestive heart failure or cardiovascular event,&#xD;
             such as an acute myocardial infarction or cerebrovascular accident;&#xD;
&#xD;
          -  Specific contra-indications for MRI imaging, including pacemakers, surgical&#xD;
             clips/material in body, metal splinters in eye, claustrophobia, or tattoos in the&#xD;
             facial area, such as permanent make-up.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Joris, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald P.M. Mensink, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

